ReviewMovement disorders clinical practice
Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners.
Review in Movement disorders clinical practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.Journal of Parkinson's disease · 2022Pooled it
- Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.Advances in therapy · 2021Pooled it
- Device aided therapies in Parkinson disease: an expert view on apomorphine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- What was first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing evidence and experience.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Starting with 24-h levodopa carbidopa intestinal gel at initiation in a large cohort of advanced Parkinson's disease patients.Scientific reports · 2024Article
- Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS.Journal of neurology · 2023Observational
- Toxin Induced Parkinsonism and Hospitalization Related Adverse Outcome Mitigation for Parkinson's Disease: A Comprehensive Review.Journal of clinical medicine · 2023Review
- Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease.Neuropsychiatric disease and treatment · 2023Review
- The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson's Disease: A Mini-Review.Frontiers in aging neuroscience · 2022Review
- 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations.CNS drugs · 2021Review
- Infusion Therapies for Parkinson's Disease.Current neurology and neuroscience reports · 2020Review
- Reply to: DUOPA® is an Excellent Alternative Treatment but with Some Caveats.Movement disorders clinical practice · 2019Article
- DUOPA Is An Excellent Alternative Treatment But With Some Caveats.Movement disorders clinical practice · 2019Article
- Response from the Editors RE: DUOPA® is an Excellent Alternative Treatment but with Some Caveats.Movement disorders clinical practice · 2019Article
- L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson's disease: real-life mobility insights from wearable sensors.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLevodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension, CLES) was approved in the United States in 2015 for the treatment of refractory motor fluctuations in individuals with Parkinson disease (PD). Many neurologists in the United States have not had personal experience with implementation and management of the unique delivery system for this treatment. METHODS AND
findingsThis educational review was developed to provide practitioners with an understanding of LCIG use from the clinician's point of view. Practical recommendations for the use of LCIG from the early planning stages through long-term patient management were compiled from the published literature, regulatory guidance, and clinical experience. Among the topics reviewed were: assembling a multidisciplinary treatment team, identifying treatment candidates, patient/care partner education, procedural considerations, post-procedural care, LCIG initiation and titration, troubleshooting issues, and ongoing monitoring. For most of these steps, a considerable amount of individualization is possible, which allows clinicians to tailor protocols based on the needs of their teams, the healthcare system, and the patient and care partner. Although clinical practices are heterogeneous, themes of early planning, ongoing education, and a team-based approach to management are universal.
conclusionsBy using established protocols and insights gleaned from experienced practitioners, clinicians who are unfamiliar with LCIG can more feasibly incorporate this treatment option into their armamentarium for treating PD motor fluctuations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.